Population
Patients with arrhythmogenic cardiomyopathy
Design
Review
Key result
MicroRNAs serve as potential biomarkers and novel therapeutic targets in arrhythmogenic cardiomyopathy by modulating gene expression and cellular processes.
Authors
Loading...
Hypothesis-generating for arrhythmogenic cardiomyopathy; prospective validation required before clinical adoption.
MicroRNAs are emerging as promising biomarkers and therapeutic targets for early identification and personalized management of arrhythmogenic cardiomyopathy.
Alcalde et al. (2023) conducted a review in Arrhythmogenic cardiomyopathy. microRNAs was evaluated. MicroRNAs serve as potential biomarkers and novel therapeutic targets in arrhythmogenic cardiomyopathy by modulating gene expression and cellular processes.